Compare Lufax Holding Ltd (LU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Lufax Holding Ltd trades at $1.37 (market cap $2.41B), while Vertex Pharmaceuticals Incorporated trades at $482.7 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 50.6× Lufax Holding Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| LU | VRTX | |
|---|---|---|
Market Cap | $2.41B | $121.95B |
Sector | Technology | Health |
52-Week High | $4.40 | $529.59 |
52-Week Low | $1.23 | $366.54 |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $1.36, down 2.16% today. The stock shows a mixed technical picture with a neutral overall signal and bearish moving averages. Fundamentally, the company reported a net loss of $2.1B on $23.1B revenue for 2025, with negative profit margins and returns. Analyst consensus is bullish with 61.5% buy ratings, but sentiment is clouded by multiple class-action lawsuits announced in May 2026 alleging securities fraud.
The outlook is cautious. While low valuation ratios (P/S 0.35, P/B 0.1) and analyst support suggest potential upside, persistent losses and significant legal overhangs pose substantial risks. Investor focus remains on the company's ability to return to profitability amid these challenges.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
